title: [Treatment of refractory and relapsed acute lymphocytic leukemia in adults].
abstract: OBJECTIVE
  To analyze on the efficacy and toxicity of fludarabine and teniposide + mitoxantrone (MIT) regimens on treating refractory and relapsed acute lymphocytic leukemia in adult patients.
  
  
  METHODS
  Teniposide 100 mg/d, 5-7 d, MIT 10 mg/d, 2 d and fludarabine regimens [Flu 30 mg/(m(2) . d), 3- 5 d, Cytarabine (Ara-c )1-2 g/(m(2) . d), 5 d; Flu 50 mg/d, 5 d, Ara-c 200 mg/d, 5 d, MIT 4 mg/d, 4 d] were used to treat 42 cases of adults with refractory and relapsed acute lymphocytic leukemia(ALL). G-CSF 5 microg/(kg . d) were used when WBC<1.0 x 10(9)/L.
  
  
  RESULTS
  In both the regimens fludarabine and VM (teniposide + MIT), the complete remission (CR) rate was 45% versus 31.8% (P>0.05); the median neutropenia began 6 days after the regimens arresting and lasting 10 versus 7.5 days, P>0.05; thrombocytopenia begin at time of 10 versus 6.5 days (P<0.05) after the regimens arresting and lasting 6 versus 10 days (P>0.05). Fludarabine regimen had less non-haematological toxic effect than that of VM.
  
  
  CONCLUSIONS
  Compared with VM, Fludarabine regimen was a very effective alternative treatment for CR induction in adult patients with refractory and relapsed ALL and low toxicity.
authors.affiliation: Institute of Hematology, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Li
authors.initials: L
authors.lastname: Bao
authors.forename: Bin
authors.initials: B
authors.lastname: Jiang
authors.forename: Xiao-jun
authors.initials: XJ
authors.lastname: Huang
authors.forename: De-bing
authors.initials: DB
authors.lastname: Wang
authors.forename: Jing-ying
authors.initials: JY
authors.lastname: Qiu
authors.forename: Xi-jing
authors.initials: XJ
authors.lastname: Lu
authors.forename: Jin
authors.initials: J
authors.lastname: Lu
authors.forename: Hong-xia
authors.initials: HX
authors.lastname: Shi
authors.forename: Feng-rong
authors.initials: FR
authors.lastname: Wang
authors.forename: Dao-pei
authors.initials: DP
authors.lastname: Lu
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D012074:Remission Induction; D012189:Retrospective Studies; D013713:Teniposide / Q000008:administration & dosage; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D003561:Cytarabine; D013713:Teniposide; D008942:Mitoxantrone; D014740:Vidarabine; C024352:fludarabine